Market Cap 370.58M
Revenue (ttm) 0.00
Net Income (ttm) -84.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,111,901
Avg Vol 1,556,954
Day's Range N/A - N/A
Shares Out 46.67M
Stochastic %K 82%
Beta 3.40
Analysts Hold
Price Target $10.00

Company Profile

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 254 4445
Address:
100 Forge Road, Suite 700 Watertown, Watertown, United States
GreylockSec
GreylockSec Jun. 23 at 11:08 PM
$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by $VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping $470 million in cash (or $8/share) and another $2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy. ....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.
0 · Reply
Stocks4thought
Stocks4thought Jun. 23 at 1:49 PM
$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
0 · Reply
Quantumup
Quantumup Jun. 23 at 12:03 PM
Canaccord Genuity reiterated $VTYX Buy-$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's disease (PD). $VIGL - $SNY Canaccord Genuity said in its note; "The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's. We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of $VTYX and reiterate our $14 12-month PT."
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 19 at 5:35 PM
$VTYX $RGLS $VIGL What kind of engineering did you study
0 · Reply
BinaryLogic
BinaryLogic Jun. 19 at 3:55 PM
$VTYX $RGLS $VIGL [Again]
0 · Reply
jacksparo
jacksparo Jun. 16 at 11:52 PM
$VERV Big pay day comes for whom the ones hold this one from my email few weeks ago!! Big move AH with buy out news! The second buy out in less than three weeks from Jack emails! Remember $VIGL And now VERV!
1 · Reply
Stocks4thought
Stocks4thought Jun. 16 at 8:03 PM
$ANIX Just like $VIGL $SGMT they rise- I believe stocks are so manipulated to the downside- to enable [positioning for huge gains- follow suit- https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
1 · Reply
BinaryLogic
BinaryLogic Jun. 14 at 11:59 PM
$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/
1 · Reply
Quantumup
Quantumup Jun. 12 at 7:15 PM
Piper Sandler, on June 9, reiterated $VTYX OW-$21 and said "we remain bullish on $VTYX's robust NLRP3 portfolio and believe these key readouts are de-risked given its straightforward MoA validated by approved IL-1ß agents." $VIGL - $SNY Piper Sandler additionally said in its note to investors:
0 · Reply
NancyPelosi____insider
NancyPelosi____insider Jun. 12 at 5:35 PM
0 · Reply
Latest News on VIGL
Sanofi to Buy Vigil Neuroscience for About $470 Million

May 21, 2025, 7:59 PM EDT - 4 weeks ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

SNY


Sanofi to acquire Vigil Neuroscience in $470 million deal

May 21, 2025, 7:29 PM EDT - 4 weeks ago

Sanofi to acquire Vigil Neuroscience in $470 million deal

SNY


Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Mar 12, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days


Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Sep 18, 2023, 2:38 PM EDT - 1 year ago

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2


GreylockSec
GreylockSec Jun. 23 at 11:08 PM
$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by $VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping $470 million in cash (or $8/share) and another $2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy. ....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.
0 · Reply
Stocks4thought
Stocks4thought Jun. 23 at 1:49 PM
$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
0 · Reply
Quantumup
Quantumup Jun. 23 at 12:03 PM
Canaccord Genuity reiterated $VTYX Buy-$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's disease (PD). $VIGL - $SNY Canaccord Genuity said in its note; "The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's. We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of $VTYX and reiterate our $14 12-month PT."
0 · Reply
ELONandTRUMP
ELONandTRUMP Jun. 19 at 5:35 PM
$VTYX $RGLS $VIGL What kind of engineering did you study
0 · Reply
BinaryLogic
BinaryLogic Jun. 19 at 3:55 PM
$VTYX $RGLS $VIGL [Again]
0 · Reply
jacksparo
jacksparo Jun. 16 at 11:52 PM
$VERV Big pay day comes for whom the ones hold this one from my email few weeks ago!! Big move AH with buy out news! The second buy out in less than three weeks from Jack emails! Remember $VIGL And now VERV!
1 · Reply
Stocks4thought
Stocks4thought Jun. 16 at 8:03 PM
$ANIX Just like $VIGL $SGMT they rise- I believe stocks are so manipulated to the downside- to enable [positioning for huge gains- follow suit- https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
1 · Reply
BinaryLogic
BinaryLogic Jun. 14 at 11:59 PM
$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/
1 · Reply
Quantumup
Quantumup Jun. 12 at 7:15 PM
Piper Sandler, on June 9, reiterated $VTYX OW-$21 and said "we remain bullish on $VTYX's robust NLRP3 portfolio and believe these key readouts are de-risked given its straightforward MoA validated by approved IL-1ß agents." $VIGL - $SNY Piper Sandler additionally said in its note to investors:
0 · Reply
NancyPelosi____insider
NancyPelosi____insider Jun. 12 at 5:35 PM
0 · Reply
Bugseason
Bugseason Jun. 5 at 9:36 PM
$SGMO its funny how a company like vigil $VIGL can get bought for 470 mil by sanofi and have a failed drug with no deep pipeline and a company like sangamo be sitting here with multiple phase 3 assets , multiple partnerships , multiple platforms and one of the deepest pipelines in genetics and not get a glimmer of a buyout. It's gotta be the poor management I'm 100% convinced .
3 · Reply
theirishreally
theirishreally Jun. 5 at 4:00 AM
$CHPT I listened to the call and feel that this is a good long term bet. I feel the company is doing better than expected in light of the interesting political situation in the US and is heading slowly in the right direction. I was in $RYCEY and $VIGL when the price had collapsed and saw similar wailing and gnashing of teeth. There is significant value in the subscriber model and contrary to some I think EVs are only going to grow. As the CEO mentioned there is a shortage of charging points in a number of markets.
3 · Reply
DonCorleone77
DonCorleone77 Jun. 4 at 11:08 AM
$VIGL Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart Vigil Neuroscience announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.
0 · Reply
MOUNTAINDEW2
MOUNTAINDEW2 Jun. 3 at 8:16 PM
$VIGL bullshitt lying bastereds
0 · Reply
BinaryLogic
BinaryLogic Jun. 2 at 8:16 PM
0 · Reply
RJLeonii
RJLeonii May. 31 at 8:31 PM
$VIGL by my math, any shares bought right now will have an automatic 28% increase after buyout. 8 per share plus 2 dollars per share paid by sanofi after the buyout.
1 · Reply
DonCorleone77
DonCorleone77 May. 27 at 9:07 PM
$VIGL Vigil Neuroscience downgraded to Hold from Buy at Stifel Stifel downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $11, following the proposed all-cash transaction by Sanofi (SNY) for $8 per share. Individuals representing 16.2% of Vigil's total common shares outstanding have already signed voting and support agreements in favor of the deal, the analyst tells investors in a research note.
0 · Reply
AlertsAndNews
AlertsAndNews May. 27 at 3:11 AM
Looking at the recent highlights here lately, some great ones that's for sure. $ASST $VIGL $GPUS $GUTS $NVTS to name a few. Link in bio for more. All trading/investing involves a risk of loss. Do your own due diligence always!
0 · Reply
I_am_retail_investor
I_am_retail_investor May. 24 at 4:36 PM
$VIGL - looking to place VIGL winnings into next bull trade. Any good <$75M marketcap diamonds in the rough out there!? 💎
4 · Reply
Baseball89
Baseball89 May. 23 at 6:02 PM
$VIGL IMRN,HYMC,EDBL,LAES and NVTS. Looking very nice
0 · Reply
topstockalerts
topstockalerts May. 23 at 2:26 PM
Morning Gainers $VIGL $NVTS $MNTN $ASST $AAP
0 · Reply
MOUNTAINDEW2
MOUNTAINDEW2 May. 23 at 12:39 PM
$VIGL lol i sold 20 days ago fml
1 · Reply